Edwards Lifesciences stock steadies after insider tax-withholding transactions

Published on 09/15/2026 at 18:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Edwards Lifesciences stock reflected per-share values around the mid-80 dollar range in mid September 2026 as insiders had shares withheld for tax on vested equity awards. The company’s stock continues to trade near levels used for these routine Form 4 transactions.

Fotorealistisches Katheterlabor mit Chirurgenteam bei minimalinvasivem Herzeingriff — Edwards Lifesciences Herzklappen-OP US28176E1082 im Katheterlabor mit Fluoroskopie-Bildschirmen und Chirurgenteam in Aktion, Illustration mit AI erstellt.

Edwards Lifesciences stock (ISIN US28176E1082) is trading around the mid-80 dollar range in mid September 2026, with recent insider Form 4 filings using per-share values of USD 86.77 and USD 84.37 to calculate tax-withholding transactions on vested equity awards dated September 11, 2026 and September 14, 2026.

Insider tax-withholding events in September 2026

According to StockTitan on September 14, 2026, Edwards Lifesciences reported in a Form 4 filing that company officer Wayne Markowitz, Corporate Vice President for the JAPAC region, had a total of 923 shares of common stock withheld to satisfy tax obligations related to vesting equity awards.

In that filing, 355 shares of Edwards Lifesciences common stock were withheld on September 11, 2026, using a per-share value of USD 86.77, while another 568 shares were withheld on September 14, 2026 at USD 84.37 per share, illustrating a modest decline of about 2.8 percent in the valuation used for tax withholding between those two dates as the stock moved from USD 86.77 to USD 84.37.

Additional insider withholding and holdings context

As StockTitan reported on September 14, 2026, a separate Form 4 filing shows that Senior Vice President and Corporate Controller Andrew M. Dahl had 253 shares of Edwards Lifesciences common stock withheld on September 13, 2026, also to cover tax obligations upon vesting of equity awards, with the shares valued at USD 84.37 per share.

The same filing notes that after this September 13, 2026 tax-withholding event, Andrew M. Dahl directly holds 14,615.41 shares of Edwards Lifesciences common stock, while the earlier Form 4 states that Wayne Markowitz’s direct holdings stand at 19,370.5581 shares following his tax-withholding transactions, giving investors a sense of the size of these executives’ remaining equity exposure.

Long-term performance snapshot for Edwards Lifesciences stock

Beyond the short-term insider activity, a long-horizon view underscores Edwards Lifesciences’ historical share price performance. As Benzinga highlighted on September 14, 2026, Edwards Lifesciences has produced an average annual return of 16.73 percent over the past 20 years, outpacing the broader market by 7.57 percentage points per year.

According to the same Benzinga analysis dated September 14, 2026, an investor who had allocated USD 100 to Edwards Lifesciences stock two decades ago would now hold a position valued at USD 2,197.52 based on a contemporaneous share price of USD 85.52, illustrating how compounding at a mid-teens annual rate has translated into more than twentyfold growth over that time span.

Stock level around mid-80 dollars as of mid September 2026

Taken together, the per-share values used in the September 11, 2026, September 13, 2026 and September 14, 2026 Form 4 tax-withholding filings at USD 86.77 and USD 84.37, alongside the USD 85.52 price referenced in the September 14, 2026 Benzinga performance analysis, suggest that Edwards Lifesciences stock is currently trading in a corridor around the mid-80 dollar mark on its primary listing in the United States. These levels provide a practical reference range for investors as of mid September 2026 in the absence of a separate, more granular same-day price snapshot.